Silexion Therapeutics (NASDAQ:SLXN) Trading Down 7.1% – Here’s Why

Posted by Joe Tyrrell on Jan 10th, 2025

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $2.10 and last traded at $2.10. 90,136 shares were traded during mid-day trading, a decline of 15% from the average session volume of 105,631 shares. The stock had previously closed at $2.26.

Wall Street Analyst Weigh In

Separately, Maxim Group assumed coverage on Silexion Therapeutics in a report on Friday, November 1st. They set a “buy” rating and a $9.00 price objective on the stock.

Check Out Our Latest Report on SLXN

Silexion Therapeutics Stock Performance

The company has a 50 day simple moving average of $2.52.

Institutional Investors Weigh In On Silexion Therapeutics

An institutional investor recently bought a new position in Silexion Therapeutics stock. Wildcat Capital Management LLC acquired a new stake in shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics makes up approximately 0.3% of Wildcat Capital Management LLC’s portfolio, making the stock its 7th biggest holding. Wildcat Capital Management LLC owned about 7.38% of Silexion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 10.95% of the company’s stock.

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.